RU 24926 | CAS#65934-61-4 | D2 receptor agonist

MedKoo Cat#: 461509 | Name: RU 24926

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RU 24926 is a di-(phenethyl)-amine derivative that acts as a dopamine-D2 receptor agonist.

Chemical Structure

RU 24926

CAS#65934-61-4

Theoretical Analysis

MedKoo Cat#: 461509

Name: RU 24926

CAS#: 65934-61-4

Chemical Formula: C19H25NO2

Exact Mass: 299.1885

Molecular Weight: 299.41

Elemental Analysis: C, 76.22; H, 8.42; N, 4.68; O, 10.69

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

RU 24926; RU24926; RU-24926;

IUPAC/Chemical Name

3,3'-((propylazanediyl)bis(ethane-2,1-diyl))diphenol

InChi Key

RVXNTMVFBHOIKH-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H25NO2/c1-2-11-20(12-9-16-5-3-7-18(21)14-16)13-10-17-6-4-8-19(22)15-17/h3-8,14-15,21-22H,2,9-13H2,1H3

SMILES Code

CCCN(CCC1=CC(O)=CC=C1)CCC2=CC(O)=CC=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 299.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Dean B, Srikanthan P, Copolov DL. Inhibition of [3H]dopamine uptake by platelets by the dopamine-D2 receptor agonist RU 24926. J Pharm Pharmacol. 1991 Jan;43(1):56-7. PubMed PMID: 1676063. 2: Fortin M, Degryse M, Petit F, Hunt PF. The dopamine D2 agonists RU 24213 and RU 24926 are also kappa-opioid receptor antagonists. Neuropharmacology. 1991 Apr;30(4):409-12. PubMed PMID: 1677169. 3: Suaudeau C, Costentin J. Analgesic effect of the direct D2 dopamine receptor agonist RU 24926 and cross tolerance with morphine. Fundam Clin Pharmacol. 1995;9(2):147-52. PubMed PMID: 7628827. 4: Simon P, Charpentier S, Costentin J. An automated method for the assessment of spontaneous and stereotyped climbing behavior in mice. Effects of the selective D1- and D2-dopamine receptor agonists SKF-38393 and RU-24926 and their association. Methods Find Exp Clin Pharmacol. 1991 Mar;13(2):99-104. PubMed PMID: 1830125. 5: Johnson EA, Tsai CE, Lucci J, Harrison-Shahan Y, Azzaro AJ. Dopamine D2 synthesis-modulating receptors are present in the striatum of the guinea pig. Neuropharmacology. 1992 Jan;31(1):95-101. PubMed PMID: 1347405. 6: Conzelmann U, Holland A, Meyer DK. Effects of selective dopamine D2-receptor agonists on the release of cholecystokinin-like immunoreactivity from rat neostriatum. Eur J Pharmacol. 1984 May 18;101(1-2):119-25. PubMed PMID: 6235119. 7: Vasse M, Protais P. Potentiation of apomorphine-induced stereotyped behaviour by acute treatment with dopamine depleting agents: a potential role for an increased stimulation of D1 dopamine receptors. Neuropharmacology. 1989 Sep;28(9):931-9. PubMed PMID: 2554186. 8: Suaudeau C, Dourmap N, Costentin J. Rapid and long lasting reduction of the hypothermic effect of a D2 dopamine agonist after an intracerebroventricular injection of 6-hydroxydopamine. Neuropharmacology. 1995 Jan;34(1):101-5. PubMed PMID: 7623958. 9: Sokoloff P, Riou JF, Martres MP, Schwartz JC. Presence of dopamine D-2 receptors in human tumoral cell lines. Biochem Biophys Res Commun. 1989 Jul 31;162(2):575-82. PubMed PMID: 2527031. 10: Yarbrough GG, McGuffin-Clineschmidt J, Singh DK, Haubrich DR, Bendesky RJ, Martin GE. Electrophysiological, biochemical and behavioral assessment of dopamine autoreceptor activation by a series of dopamine agonists. Eur J Pharmacol. 1984 Mar 16;99(1):73-8. PubMed PMID: 6723791. 11: Simon P, Panissaud C, Costentin J. Anxiogenic-like effects induced by stimulation of dopamine receptors. Pharmacol Biochem Behav. 1993 Jul;45(3):685-90. PubMed PMID: 8101381. 12: Ladurelle N, Duterte-Boucher D, Costentin J. Stimulation of D1 and D2 dopamine receptors produces additive anorectic effects. Fundam Clin Pharmacol. 1991;5(6):481-90. PubMed PMID: 1683341. 13: Michael-Titus A, Bousselmame R, Costentin J. Stimulation of dopamine D2 receptors induces an analgesia involving an opioidergic but non enkephalinergic link. Eur J Pharmacol. 1990 Oct 9;187(2):201-7. PubMed PMID: 2176983. 14: Costentin J, Duterte-Boucher D, Panissaud C, Michael-Titus A. Dopamine D1 and D2 receptors mediate opposite effects of apomorphine on the body temperature of reserpinized mice. Neuropharmacology. 1990 Jan;29(1):31-5. PubMed PMID: 1968237. 15: Kreiss DS, Bergstrom DA, Gonzalez AM, Huang KX, Sibley DR, Walters JR. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur J Pharmacol. 1995 Apr 24;277(2-3):209-14. PubMed PMID: 7493610. 16: Enjalbert A, Bockaert J. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Mol Pharmacol. 1983 May;23(3):576-84. PubMed PMID: 6306429. 17: Penit-Soria J, Retaux S, Maurin Y. [Effects of the stimulation of D1 and D2 dopaminergic receptors on the electrically induced release of gamma-(3H)-aminobutyric acid in the prefrontal cortex of the rat]. C R Acad Sci III. 1989;309(10):441-6. French. PubMed PMID: 2514970. 18: Suaudeau C, Bousselmame R, Costentin J. A different balance in the sensitivity of D1 and D2 dopamine receptors accounts for differences in apomorphine-induced hypothermic effects in Swiss and C3H mice. Neuropharmacology. 1992 Nov;31(11):1115-9. PubMed PMID: 1475020. 19: Sonsalla PK, Gibb JW, Hanson GR. Opposite responses in the striato-nigral substance P system to D1 and D2 receptor activation. Eur J Pharmacol. 1984 Oct 1;105(1-2):185-7. PubMed PMID: 6208043. 20: Lantin Le Boulch N, Truong-Ngoc NA, Gauchy C. Role of dendritic dopamine of the substantia nigra in the modulation of nigrocollicular gamma-aminobutyric acid release: in vivo studies in the rat. J Neurochem. 1991 Sep;57(3):1080-3. PubMed PMID: 1677673.